Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 20Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 11Hodgkin Disease 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Gliosarcoma 3Glioblastoma 3Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Hairy Cell 2Leukemia 2Hematologic Neoplasms 2Glioma 2Burkitt Lymphoma 2Warts 1Waldenstrom Macroglobulinemia 1Sarcoma, Myeloid 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Lenalidomide 2plerixafor 1ofatumumab 1SARS-CoV-2 inactivated vaccines 1Influenza Vaccines 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Agammaglobulinemia × plerixafor × Clear all
NCT02231879 2023-04-07

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2/3 Completed
20 enrolled 10 charts

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡